Abeona Therapeutics Inc vs ADMA Biologics Inc — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while ADMA Biologics Inc trades at $9.91 (market cap $2.22B). The key difference: ADMA Biologics Inc is far larger — about 5.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ADMA | |
|---|---|---|
Market Cap | $421.19M | $2.22B |
Sector | Health | Health |
52-Week High | $7.45 | $20.38 |
52-Week Low | $4.17 | $7.60 |
Enterprise Value | $276.10M | $2.29B |
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →